<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520103</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-MAM-0110</org_study_id>
    <secondary_id>2011-001024-38</secondary_id>
    <secondary_id>CRAD001JDE38T</secondary_id>
    <nct_id>NCT01520103</nct_id>
  </id_info>
  <brief_title>Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer</brief_title>
  <acronym>VicTORia</acronym>
  <official_title>Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is Examination of the superiority of a combination of vinorelbine
      with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in
      advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessment over 36 months, minimum 12 month</time_frame>
    <description>Progression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Assessment over 36 months</time_frame>
    <description>Capture all adverse events, serious adverse events, all side effects of the study medication, serious side effects, adverse events that lead to temporary or complete discontinuation of the study treatment and the Rates and causes of death.
A safety interims analysis is planned, as soon as 60 subjects have finished at least two treatment cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression Free Survival after 6 months (6 months PFSR)</measure>
    <time_frame>Assessment over 36 months</time_frame>
    <description>descriptive Evaluation, for the monotherapy (arm 2) a median PFS of 4 months is assumed. It is expected that the combination therapy will prolong the median PFS to 6.5 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>The duration of overall survival (OS) will be determined by measuring the time interval from randomization to the date of death or last observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR, PR)</measure>
    <time_frame>36 months</time_frame>
    <description>The tumour status of patients will be evaluated nine weekly during the treatment until detection of progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Her2-negative Metastatic Breast Cancer</condition>
  <condition>Her2-negative Locally Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vinorelbin and Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vinorelbin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorebine, Everolimus</intervention_name>
    <description>Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress</description>
    <arm_group_label>Vinorelbin and Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress</description>
    <arm_group_label>standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 .Dated and signed patient informed consent before start of any in the protocol specified
        procedures 2. Histologically or cytologically confirmed Her2/neu negative, metastatic or
        locally advanced breast cancer, including inoperable local relapse, with measurable or
        non-measurable lesions for which

          -  a palliative second line chemotherapy is indicated. Antihormone palliative
             pretreatments do not count as separate treatment lines

          -  treatment with anthracycline and/or taxanes has failed or is not suitable

          -  which cannot be adequately treated by operation or radiotherapy on its own 3. An
             exclusive anti-hormone therapy is not indicated for the patient 4. ECOG Performance
             Status of 0-2 5. Women &gt;= 18 years of age 6. Life expectancy of at least 12 weeks 7.
             Adequate bone marrow, liver and renal function (according to SmPC of Vinorelbine,
             Afinitor®) based on laboratory assessments raised within 7 days prior to start of
             study treatment:

          -  Haemoglobin &gt;= 9.0 g/dl

          -  Absolute neutrophil count (ANC) &gt;= 2/mm³

          -  Thrombocytes &gt;= 100/µl

          -  INR &gt;= 2

          -  Serum bilirubin =&lt; 1.5x upper limit of normal ( in patients with known Gilbert
             syndrome, total bilirubin =&lt; 3x upper limit of normal, with direct bilirubin =&lt; 1.5x
             upper limit of normal

          -  ALT and AST =&lt; 2.5x upper limit of normal (=&lt; 5x upper limit of normal in subjects
             with liver metastases)

          -  Serum cholesterol =&lt; 300 mg/dl or 7.75 mmol/l and triglycerides =&lt; 2.5x upper limit of
             normal (with lipid lowering drugs permitted)

          -  Serum creatinin =&lt; 2x upper limit of normal 8. Documentation of a negative pregnancy
             test in women of childbearing potential within 7 days prior to start of study. Sexual
             active pre-menopausal women are required to use adequate contraception throughout the
             duration of the study, except for oestrogen containing contraceptives

        Exclusion Criteria:

          1. Previous treatment with Vinorelbine or an inhibitor of mTOR

          2. Treatment with other study medication within 28 days before start of treatment

          3. Patients who have received prior radiotherapy to ≥ 25% of the bone marrow

          4. Other tumours in the previous 5 years with exception of an adequately treated basal
             cell carcinoma of the skin or a preinvasive cervix carcinoma

          5. Simultaneous use of known CYP3A4 inducers (e.g. Phenytoin, Rifampicin) or inhibitors
             of this enzyme (e.g. Itraconazole, Ketoconazole), therefore also use of mistletoe, St
             John's wort or grapefruit juice

          6. Patients to whom at least one of the conditions applies:

               -  Substance abuse

               -  medical, psychological or social conditions that may interfere with the patient's
                  participation in the study or evaluation of the study results as judged by the
                  investigator

               -  Legal incapacity or limited legal capacity

               -  Subjects who are unable to take oral medication

               -  Any condition that could jeopardise the safety of the patient and their
                  compliance in the study as judged by the investigator

          7. History of cardiac dysfunction including one of the following:

               -  Myocardial infarction by elevated cardiac enzymes or persistent regional wall
                  abnormalities on assessment of LV function

               -  History of documented congestive heart failure (NYHA ≥ 3)

               -  Documented cardiomyopathy

          8. Known HIV infection or chronic hepatitis B or C or history of hepatitis B / C

          9. Active clinically relevant infection (&gt; grade 2 NCI-CTC Version 4.03)

         10. Clinical or radiological detection of CNS metastases

         11. Patients receiving concomitant immunosuppressive agents or chronic use of
             corticosteroids at the time of study entry except in cases outlined below:

               -  topical applications (e.g. rash,) inhaled sprays, (e.g. obstructive airway
                  diseases) eye drops or local injections (e.g. intraarticular) are allowed

         12. Active bleeding diathesis or an oral anti-vitamin K medication (except low-dose
             warfarin and aspirin or equivalent, as long as the INR ≤ 2)

         13. Kidney function disorder requiring dialysis

         14. Seriously impaired liver function (Child-Pugh, class C)

         15. Known hypersensitivity reaction to Vinorelbine or Everolimus

         16. Pregnant or breast-feeding subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Lerchenmüller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hämatologisch-onkologische Gemeinschaftspraxis, Münster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Gemeinschaftspraxis, Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>AIO - Working Group for Medical Oncology from the German Cancer Society</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>locally advanced breast cancer</keyword>
  <keyword>Her2/new negative</keyword>
  <keyword>HER2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

